|
Milt McColl joined New Leaf as a Venture Partner in April
2007. Prior to joining New Leaf, Milt was President of the
Neurovascular Division of Boston Scientific Corporation
(BSC). Milt initially joined BSC in 2001 following the
acquisition of Embolic Protection, Inc (EPI) where he served
as Vice President and General Manager for the Embolic
Protection Franchise, part of the Interventional Cardiology
division of BSC. Milt joined EPI in 2000 as one of the first
employees assuming the position of Vice President of
Clinical, Regulatory and Quality Affairs and Medical
Director. During his time there he managed the design,
implementation and successful completion of the FIRE
Clinical trial, an 800 patient pivotal study which led to
the FDA clearance of the FilterWire EX™ Device. Previously,
Milt was the President and Chief Executive Officer of
Genitope, Inc. an early stage biotechnology company focusing
on patient-specific therapies for lymphoma which eventually
became publically traded. Before joining Genitope, Milt was
President and Chief Executive Officer of CSFluids, Inc.
(later renamed Eunio), a development-stage company offering
a surgical treatment for Alzheimer's Disease. Prior to that
he was Vice President of Regulatory Affairs, Quality
Affairs, Clinical Affairs and Chief Medical Officer for
Gynecare, Inc. (eventually acquired by Johnson and Johnson)
and Director of Marketing for Origin Medsystems (acquired by
Guidant Corporation).
Milt began his career as a professional football player with
the San Francisco Forty-Niners and Los Angeles Raiders from
1981 to 1989. He was a member of two Super Bowl Championship
teams for the Forty-Niners and was a special team’s captain.
Milt earned a B.S. in Biology from Stanford University and
his M.D. from Stanford University School of Medicine.
Board Seats:
Glumetrics,
IlluminOss Medical,
Interlace Medical
Contact Information:
milt@nlvpartners.com
(650) 234-2700
|
 |
